Exposing drug industry funding of UK patient organisations

Piotr  Ozieranski; Emily  Richard; Shai Mulinari

doi:10.1136/bmj.l1806

Exposing drug industry funding of UK patient organisations

Piotr Ozieranski, Emily Richard, Shai Mulinari

Sociologi

University of Bath

Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

94 Nedladdningar (Pure)

Sammanfattning

From 2012 to 2016 the drug industry donated over £57m (€65m; $73m) to UK patient organisations, with the annual sum more than doubling over the period. The funding benefited a small number of organisations and activities related to research and public involvement. The industry gave priority to commercially high profile conditions. Industry payment disclosures had limited transparency

Originalspråk	engelska
Artikelnummer	l1806
Tidskrift	BMJ: British Medical Journal
Volym	365
DOI	https://doi.org/10.1136/bmj.l1806
Status	Published - 2019 maj 23

Ämnesklassifikation (UKÄ)

Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi
Sociologi (exklusive socialt arbete, socialpsykologi och socialantropologi)

Tillgång till dokument

10.1136/bmj.l1806Licens: CC BY-ND

bmj.l1806.fullPublicerad version, 910 KB

7 Artikel i vetenskaplig tidskrift

Advancing international comparison of pharmaceutical industry funding of patient advocacy: Focus on Denmark
Mulinari, S., Pashley, D. & Ozieranski, P., 2022 nov. 8, I: Health Policy. 126, 12, s. 1256-1262
Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

Öppen tillgång
Fil
9 Nedladdningar (Pure)
Five years of pharmaceutical industry funding of patient organisations in Sweden: cross-sectional study of companies, patient organisations and drugs
Mulinari, S., Vilhelmsson, A. J., Rickard, E. & Ozieranski, P., 2020 juni 24, I: PLoS ONE. e.0235021.
Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

Öppen tillgång
Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016)
Ozieranski, P., Csanadi, M., Rickard, E. & Mulinari, S., 2020 sep. 20, I: BMJ Open. 10, 9, s. 1-11 10:e037351.
Forskningsoutput: Tidskriftsbidrag › Artikel i vetenskaplig tidskrift › Peer review

Öppen tillgång

1 Avslutade

Vad kan vi lära oss från läkemedelsindustrins nya värdeöverföringsdatabaser? En policy- och nätverksstudie av relationer mellan företag och sjukvårdspersonal- och organisationer i fyra EU-länder
Mulinari, S., Ozieranski, P. & King, L.
Swedish Council for Working Life and Social Research (Forte)
2017/01/01 → 2021/12/31
Projekt: Forskning

Citera det här

@article{3fb083e864e44cf88f807a9e40001a60,

title = "Exposing drug industry funding of UK patient organisations",

abstract = "From 2012 to 2016 the drug industry donated over £57m (€65m; $73m) to UK patient organisations, with the annual sum more than doubling over the period. The funding benefited a small number of organisations and activities related to research and public involvement. The industry gave priority to commercially high profile conditions. Industry payment disclosures had limited transparency",

author = "Piotr Ozieranski and Emily Richard and Shai Mulinari",

year = "2019",

month = may,

day = "23",

doi = "10.1136/bmj.l1806",

language = "English",

volume = "365",

journal = "BMJ: British Medical Journal",

issn = "1756-1833",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Exposing drug industry funding of UK patient organisations

AU - Ozieranski, Piotr

AU - Richard, Emily

AU - Mulinari, Shai

PY - 2019/5/23

Y1 - 2019/5/23

N2 - From 2012 to 2016 the drug industry donated over £57m (€65m; $73m) to UK patient organisations, with the annual sum more than doubling over the period. The funding benefited a small number of organisations and activities related to research and public involvement. The industry gave priority to commercially high profile conditions. Industry payment disclosures had limited transparency

AB - From 2012 to 2016 the drug industry donated over £57m (€65m; $73m) to UK patient organisations, with the annual sum more than doubling over the period. The funding benefited a small number of organisations and activities related to research and public involvement. The industry gave priority to commercially high profile conditions. Industry payment disclosures had limited transparency

U2 - 10.1136/bmj.l1806

DO - 10.1136/bmj.l1806

M3 - Article

C2 - 31122928

VL - 365

JO - BMJ: British Medical Journal

JF - BMJ: British Medical Journal

SN - 1756-1833

M1 - l1806

ER -

Exposing drug industry funding of UK patient organisations

Sammanfattning

Ämnesklassifikation (UKÄ)

Tillgång till dokument

Fingeravtryck

Forskningsoutput

Advancing international comparison of pharmaceutical industry funding of patient advocacy: Focus on Denmark

Five years of pharmaceutical industry funding of patient organisations in Sweden: cross-sectional study of companies, patient organisations and drugs

Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016)

Projekt

Vad kan vi lära oss från läkemedelsindustrins nya värdeöverföringsdatabaser? En policy- och nätverksstudie av relationer mellan företag och sjukvårdspersonal- och organisationer i fyra EU-länder

Citera det här